Ascentage Pharma Group (AAPG) reported a 2025 loss late Wednesday of 3.49 Chinese renminbi ($0.50) per diluted share, widening from a loss of 1.34 renminbi a year earlier.
Two analysts polled by FactSet expected 2.22 renminbi.
Revenue for the year ended Dec. 31 was 574.1 million renminbi, compared with 980.7 million renminbi a year earlier.
Four analysts polled by FactSet expected 525.3 million renminbi.
As of Dec. 31, 2025, cash and bank balances were $353.2 million, compared with $172.8 million a year earlier.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments